A 48-year-old woman with CKD stage 5 on hemodialysis presents with fatigue and dyspnea. Hemoglobin is 8.2 g/dL, serum creatinine is 9.8 mg/dL, and iron studies show normal ferritin but low transferrin saturation. What is the most common cause of anemia in this patient?

Explanation

## Anemia in CKD: Etiology and Epidemiology **Key Point:** Erythropoietin (EPO) deficiency is the most common cause of anemia in CKD, accounting for 80–90% of anemia cases in dialysis patients. ### Pathophysiology of EPO Deficiency 1. **Progressive renal function loss** → ↓ peritubular fibroblast mass 2. **Reduced EPO production** (kidneys produce ~90% of EPO) 3. **Inadequate erythropoiesis** despite normal iron and B12 4. **Normocytic, normochromic anemia** develops ### Differential Diagnosis of CKD Anemia | Cause | Prevalence | Iron Studies | RBC Indices | Key Finding | |-------|-----------|--------------|-------------|-------------| | **EPO deficiency** | 80–90% | Normal | Normocytic | ↓ Retic count | | **Iron deficiency** | 10–20% | ↓ Ferritin, ↓ TSAT | Microcytic | Chronic blood loss | | **Hemolysis** | <5% | Normal | Normocytic | ↑ Retic, ↑ LDH | | **Aluminum toxicity** | Rare (modern era) | Normal | Normocytic | Microcytic anemia + bone disease | **High-Yield:** In this patient, **normal ferritin but low transferrin saturation** does NOT indicate iron deficiency—it suggests **functional iron deficiency** (iron is present but not available for erythropoiesis), which is secondary to EPO deficiency and inflammation. ### Why EPO Deficiency in This Case? - **CKD stage 5 on dialysis** → severe renal function loss - **Normocytic anemia** (Hb 8.2) → rules out microcytic iron deficiency - **Normal ferritin** → adequate iron stores - **Low TSAT** → functional iron deficiency (common in EPO-deficient anemia) - **Fatigue and dyspnea** → classic EPO deficiency symptoms **Clinical Pearl:** Functional iron deficiency in CKD occurs because EPO deficiency reduces erythropoiesis, so iron uptake by erythroid precursors is low despite normal stores. Iron studies alone can be misleading; clinical context is essential. ### Management Algorithm ```mermaid flowchart TD A[CKD Anemia]:::outcome --> B{Ferritin and TSAT?}:::decision B -->|Low ferritin| C[Iron deficiency]:::action C --> D[IV iron supplementation]:::action B -->|Normal ferritin, low TSAT| E[Functional iron deficiency]:::action E --> F[Assess EPO responsiveness]:::decision F -->|EPO deficiency| G[ESA therapy]:::action F -->|EPO resistance| H[Investigate inflammation, infection]:::decision B -->|High ferritin| I[Iron overload or inflammation]:::outcome ``` ### ESA Therapy Principles 1. **Target Hb:** 10–12 g/dL (avoid overcorrection → thrombosis risk) 2. **Initial agent:** Epoetin alfa or darbepoetin alfa 3. **Dosing:** Titrate based on Hb response 4. **Iron supplementation:** Concurrent IV iron to support erythropoiesis 5. **Monitor:** Monthly Hb, TSAT, ferritin **Warning:** Overcorrection of anemia (Hb >13 g/dL) increases cardiovascular and thromboembolic events. [cite:Harrison 21e Ch 280; KDIGO 2012 Anemia Guidelines]